博雅生物(300294) - 2024 Q4 - 年度业绩预告

Financial Performance Expectations - The company expects net profit attributable to shareholders to be between 38,000 and 48,000 thousand yuan, representing a year-on-year growth of 60.03% to 102.14% compared to 23,746 thousand yuan in the previous year[3]. - The net profit after deducting non-recurring gains and losses is projected to be between 28,374 and 38,374 thousand yuan, indicating a year-on-year increase of 98.32% to 168.22% from 14,307 thousand yuan last year[3]. - Basic earnings per share are expected to be between 0.75 and 0.95 yuan per share, compared to 0.47 yuan per share in the previous year[3]. Revenue and Operational Highlights - The main reason for the performance change is the increase in revenue from blood products and the low base effect from goodwill impairment and other asset impairment in the previous year[5]. - The company achieved a plasma collection volume of 522.04 tons from 16 operating plasma stations, marking an 11.71% year-on-year growth[5]. Non-Recurring Gains and Losses - The estimated impact of non-recurring gains and losses on net profit is approximately 9,626 thousand yuan[5]. Audit and Reporting - The financial data in this earnings forecast has not been audited by a registered accounting firm[4]. - The specific data will be detailed in the company's 2024 annual report[7]. Investment Advisory - Investors are advised to make cautious decisions and be aware of investment risks[7]. - The earnings forecast period is from January 1, 2024, to December 31, 2024[3].